Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients: Recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplation

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 6 A, 2000, Pages 659-734

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0348116722     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (411)

1. Institute of Medicine/Committee on Emerging Microbial Threats to Health. Emerging infections: microbial threats to health in the United States. Lederberg J, Shope RE, and Oaks SC Jr., eds. Washington, DC: National Academy Press, 1992. Available at 〈http://books.nap.edu/ books/0309047412/html/index.html〉. Accessed June 28, 2000.
2. CDC. Addressing emerging infectious disease threats: a prevention strategy for the United States. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1994. Available at 〈http://www.cdc.gov/ncidod/publications/eid_plan〉. Accessed May 17, 2000.
3. CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44(No. RR-8):1-34.
4. CDC. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1997;46(No. RR-12):1-46.
5. CDC. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1999;48(No. RR-10):1-66.
6. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis 1994;18(3):421.
7. Appelbaum FR. Use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. CA Cancer J Clin 1996;46(3):142-64.
8. Kessinger A, Armitage JO. Use of peripheral stem cell support of high-dose chemotherapy. In: DeVita VT Jr., Hellman S, Rosenberg SA, eds. Important advances in oncology 1993. Philadelphia, PA: J.B.Lippincott Co. 1993.
9. Bortin MM, Horowitz MM, Gale RP, et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 1992;268(5):607-12.
10. Sobocinski KA, Horowitz MM, Rowlings PA, et al. Bone marrow transplantation - 1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. J Hematother 1994;3:95-102.
11. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995;332(4):217-23.
12. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104(2):155-63.
13. Storb R, Longton G, Anasetti C, et al. Changing trends in marrow transplantation for aplastic anemia [Review]. Bone Marrow Transplant 1992;10(suppl 1):45-52.
14. Mackinnon S, Hows JM, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol 1990;18(5):421-5.
15. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328(9):593-602.
16. Nademanee AP, Schmidt GM, Parker P, et al. Outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995;86:1228-34.
17. Clift RA, Hansen JA, Thomas ED, et al. Marrow transplantation from donors other than HLA-identical siblings. Transplant 1979;28(3):235-42.
18. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313(13):765-71.
19. Ferrara JL, Deeg HJ. Graft-versus-host disease [Review]. N Engl J Med 1991;324(10):667-74.
20. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78(8):2120-30.
21. Rowlings PA. 1996 summary slides show current use and outcome of blood and marrow transplantation. Autologous Blood & Marrow Transplant Registry - North America: ABMTR Newsletter 1996;3(1):6-12.
22. Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored placental blood for unrelated bone marrow reconstitution [Review]. Blood 1993;81(7):1679-90.
23. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335(3):157-66.
24. Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996;88(3):795-802.
25. Meropol NJ, Overmoyer BA, Stadtmauer EA. High-dose chemotherapy with autologous stem cell support for breast cancer. Oncology (Huntingt) 1992;6(12):53-60, 63; discussion, 63-4, 69; published erratum, Oncology (Huntingt) 1993;7(3):105.
26. Sullivan KM, Storek J, Kopecky KJ, et al. Controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996;2(1):44-53.
27. Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treatment of acute graft-versus-host disease: the old and the new; a report from The Eastern Cooperative Oncology Group (ECOG) [Review]. Bone Marrow Transplant 1997;19(6):577-600.
28. Antman KH, Rowlings PA, Vaughn WP, et al. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol 1997;15(5):1870-9.
29. Nevill TJ, Shepherd JD, Nantel SH, et al. Stem cell transplant-related mortality (TRM) 1985-1996: the Vancouver experience [Abstract 4426]. Blood 1997;90(10)(suppl 1 [part 2 of 2]):373b.
30. Duell T, van Lint MT, Ljungman P, et al. Health and functional status of long-term survivors of bone marrow transplantation. Ann Intern Med 1997;126(3):184-92.
31. Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation. Soc Sci Med 1995;40(4):479-90.
32. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995;86(10):3979-86.
33. Pearson ML. Guideline for prevention of intravascular device-related infections. Part I. Intravascular device-related infections: an overview. Am J Infect Control 1996;24:262-93.
34. Paulin T, Ringdén O, Lönnqvist B. Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. Transplant 1985;39(4):377-84.
35. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330(12):827-38.
36. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation (second of two parts) [Review]. N Engl J Med 1975;292(17):895-902.
37. Yeager AM, Vogelsang GB, Jones RJ, et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992;79(11):3031-5.
38. Rinehart JJ, Balcerzak SP, Sagone AL, LoBuglio AF. Effects of corticosteroids on human monocyte function. J Clin Invest 1974;54(6):1337-43.
39. Atkinson K, Horowitz MM, Gale RP, et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 1989;4(3):247-54.
40. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28(3):250-9.
41. Witherspoon RP, Storb R, Ochs HD, et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981;58(2):360-8.
42. Lum LG, Munn NA, Schanfield MS, Storb R. Detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 1986;67(3):582-7.
43. Ambrosino DM, Molrine DC. Critical appraisal of immunization strategies for the prevention of infection in the compromised host. Hematol Oncol Clin North Am 1993;7(5):1027-50.
44. Lum LG. Kinetics of immune reconstitution after human marrow transplantation. Blood 1987;69(2):369-80.
45. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69(2):204-17.
46. Izutsu KT, Sullivan KM, Schubert MM, et al. Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. Transplant 1983;35(5): 441-6.
47. Aucouturier P, Barra A, Intrator L, et al. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood 1987;70(3):779-85.
48. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever [Review]. Clin Infect Dis 1997;25(3): 551-73.
49. Pizzo PA, Hathorn JW, Hiemenz J, et al. Randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315(9):552-8.
50. th edition. Montvale, NJ: Medical Economics Company, Inc., 2000:528-33.
51. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996(4);23:795-805.
52. Murphy M, Brown AE, Sepkowitz KA, et al. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer - is it justified [Letter]? Clin Infect Dis 1997;25(2):346-8.
53. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994;330(17):1240-1.
54. Kirkpatrick BD, Harrington SM, Smith D, et al. Outbreak of vancomycin-dependent Enterococcus faecium in a bone marrow transplant unit. Clin Infect Dis 1999;29(5):1268-73.
55. Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors. J Clin Oncol 1995;13(4):1023-35.
56. Rand KJ, Houck H, Ganju A, Babington RG, Elfenbein GJ. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. Bone Marrow Transplant 1989;4(6):679-83.
57. Bosi A, De Majo E, Guidi S, et al. Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients. Haematologica 1990;75(2):109-12.
58. Buckley RH, Schiff RI. Use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325(2):110-7.
59. rd edition. New York, NY: Plenum Medical Book Co., 1994:601-28.
60. Sullivan KM, Storek J, Kopecky KJ, et al. Controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-versus-host disease following marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996;2:44-53.
61. Wolff SN, FayJW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 1993;118(12):937-42.
62. Garner JS. Guideline for isolation precautions in hospitals. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17(1):53-80; published erratum, Infect Control Hosp Epidemiol 1996;17(4):214.
63. CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-8):1-24.
64. Winston DJ, Schiffman G, Wang DC, et al. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 1979;91(6):835-41.
65. Hammarström V, Pauksen K, Azinge J, et al. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support Care Cancer 1993;1:195-9.
66. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplant 1994;57(5):677-84.
67. nd ed. Oxford, England: Blackwell Science, Inc., 1999;751-63.
68. Alcaide F, Linares JA, Pallares R, et al. In vitro activities of 22 ß-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group Streptococci isolated from blood. Antimicrob Agents Chemother 1995;39(10):2243-7.
69. Steiner M, Villablanca J, Kersey J, et al. Viridans strptococcal shock in bone marrow transplant patients. Am J Hematol 1993;42(4):354-8.
70. th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:262-72.
71. CDC. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1993;42(No.RR-13):1-15.
72. Granoff DM, Basden M. Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease. J Infect Dis 1980;141(1):40-6.
73. Band JD, Fraser DW, Ajello G. Prevention of Haemophilus influenzae type b disease. JAMA 1984;251(18):2381-6.
74. Band JD, Fraser DW, Hightower AW, Broome CV. Prophylaxis of Haemophilus influenzae type b disease [Letter]. JAMA 1984;252(23):3249-50.
75. Barra A, Cordonnier C, Prezilosi MP, et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow transplant recipients. J Infect Dis 1992;166(5):1021-8.
76. Sable CA, Donowitz GA. Infections in bone marrow transplant recipients. Clin Infect Dis 1994;18(3):273-84; quiz 282-4.
77. Roy V, Ochs L, Weisdorf D. Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis [Review]. Leuk Lymphoma 1997;26(1-2):1-15.
78. Bowden RA, Slichter SJ, Sayers M, et al. Comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplantation. Blood 1995;86(9):3598-603.
79. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double blind study. Blood 1996;88(10):4063-71.
80. Boeckh M, Stevens-Ayers T, Bowden R. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 1996;174(5):907-12.
81. Boeckh M, Bowden R. Cytomegalovirus infection in marrow transplantation. In: Buckner CD, Clift RA, ed. Technical and biological components of marrow transplantation. Boston, MA: Kluwer Academic Publishers, 1995:97-136.
82. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effect of antiviral therapy after bone marrow transplantation. Blood 1995;86(7):2815-20.
83. rd ed., revised and expanded. New York, NY: Marcel Decker, Inc., 1999: 361-72.
84. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplant. N Engl J Med 1991;325(23):1601-7.
85. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. Randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl J Med 1991;324(15):1005-11.
86. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G. Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118(3):173-8.
87. Mazzulli T, Drew LW, Yen-Lieberman B, et al. Multicenter comparison of the Digene Hybrid Capture CMV DNA Assay (Version 2.0), the pp65 antigenemia assay, and cell culture for the detection of cytomegalovirus viremia. J Clin Microbiol 1999;37(4):958-63.
88. Gerna G, Baldanti F, Middeldorp JM, et al. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J Clin Microbiol 1999;37(4):902-11.
89. Singhal S, Mehta J, Powles R, et al. Three weeks of ganciclovir for cytomegalovirus after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15(5):777-81.
90. Verdonck LF, Dekker AW, Rozenberg-Arska M, van den Hoek MR. Risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 1997;24(5): 901-7.
91. Zaia J, Gallez-Hawkins GM, Longmate J, et al. Late bacterial and fungal sepsis and mortality after BMT are increased by duration of early ganciclovir preemptive therapy for CMV infection [Abstract 2128]. Blood 1998;92(10)(suppl 1 [part 1 of 2]):518a.
92. Bacigalupo A, Bregante S, Tedone E, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hematopoietic stem cell transplantation. Transplant 1996;62(3);376-80.
93. Moretti S, Zikos P, Van Lint MT, et al. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hematopoietic stem cell transplantation (HSCT): a randomized study. Bone Marrow Transplant 1998;22(2):175-80.
94. Boeckh M, Hoy C, Torok-Storb B. Occult cytomegalovirus infection of marrow stroma. Clin Infect Dis 1998;26(1):209-10.
95. Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for CMV-specific T-cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997;19(11):1111-16.
96. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998;21(6):597-605.
97. Zaia JA, Gallez-Hawkins GM, Teftmeier BR, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997;176(3):782-5.
98. Ljungman P, Aschan J, Azinge JN, et al. Cytomegalovirus viremia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol 1993;83(1):118-24.
99. Lazzarotto T, Varani S, Spezzacatena P, et al. Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients. J Infect Dis 1998;178(4):1145-9.
100. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplant 1997;64(1):108-13.
101. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994;343(8900):749-53.
102. Boeckh M, Gooley TA, Bowden RA. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis 1998;178(4):1153-7.
103. Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowden RA. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995;172(4):939-43.
104. th ed. Washington, DC: American Public Health Association, 2000:350-2.
105. Papadopoulos E, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994;330(17):1185-91.
106. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92(5):1549-55.
107. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphopro-liferative disorders following bone marrow transplantation. Blood 1988;71(5): 1234-43.
108. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988;72(2):520-9.
109. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305(2):63-7.
110. Gluckman E, Lotsberg J, Devergie A, et al. Prophylaxis of herpes infections after bone marrow transplantation by oral acyclovir. Lancet 1983;2(8352):706-8.
111. Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982;96(3):265-9.
112. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex reactivation after marrow transplantation. Ann Intern Med 1984;100(6):823-8.
113. Johnson JR, Egaas S, Gleaves CA, Hackman R, Bowden RA. Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin Infect Dis 1992;14(1):38-45.
114. Crumpacker CS. Ganciclovir [Review]. New Engl J Med 1996;335(10):721-9.
115. th annual meeting, September 18-20, 1996, New Orleans, Louisiana;55.
116. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors, and complications. Bone Marrow Transplant 1994;13(3):277-83.
117. Lawrence R, Gershon AA, Holzman R, Steinberg SP. Risk of zoster after varicella vaccination in children with leukemia. New Engl J Med 1988;318(9):543-8.
118. Locksley RM, Fluornoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985;152(6):1172-81.
119. Schuchter LM, Wingard J, Piantadose S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989;74(4):1424-27.
120. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(No. RR-11):1-36.
121. CDC. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-06):1-5.
122. Wacker P, Hartmann O, Benhamou E, Salloum E, Lamerle J. Varicellazoster virus infections after autologous bone marrow transplantation in children. Bone Marrow Transplant 1989;4(2):191-4.
123. Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 1988;158(1):238-41.
124. th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:351-9.
125. Selby PJ, Powles RL, Easton D, et al. Prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989;59(3):434-8.
126. Ljungman P, Wilczek H, Gahrton G, et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation to herpes antigens in vitro. Bone Marrow Transplant 1986;1(2):185-92.
127. Cirrelli R, Herne K, McCrary M, Lee P, Tyrine, SK. Famciclovir: review of clinical efficacy and safety [Review]. Antiviral Res 1996;29(2-3):141-51.
128. Cat LK, Yamauchi NK. Varicella vaccine in immunocompromised patients [Review]. Annuals of Pharmacology 1996;30(2):181-4.
129. Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997;176(3):578-85.
130. Garcia R, Raad I, Abi-Said D, et al. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol 1997;18(6):412-6.
131. Raad I, Abbas J, Whimbey E. Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med 1997;102(3A):48-52.
132. Sable CA, Hayden FG. Orthomyxoviral and paramyxoviral infections in transplant patients [Review]. Infect Dis Clin North Am 1995;9(4):987-1003.
133. Whimbey E, Champlin R, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996;22(5):778-82.
134. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997;102(3A):10-8.
135. Bowden RA. Respiratory virus infections in bone marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997;102(3A):27-30.
136. Harrington RD, Hooton RD, Hackman RC, et al. Outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165(6):987-93.
137. Whimbey E, Champlin R, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995;16(3):393-9.
138. Folz RJ, Elkordy MA. Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer. Chest 1999;115(3):901-5.
139. Whimbey E, Elting LS, Couch RB, et al. Influenza A virus infection among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994;13(4):437-40.
140. CDC. Guideline for prevention of nosocomial pneumonia. Respiratory Care 1994;39(12): 1191-236.
141. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-3):1-38.
142. Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993;11(1):1-5.
143. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997;102(3A):55-60.
144. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282(1):31-5.
145. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. New Engl J Med 1999;341(18):1336-43.
146. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1991:1.
147. CDC. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR 1999;48(No. RR-14):1-10.
148. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998;26(6):1418-24.
149. Klimov AI, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995;172(5):1352-55.
150. Knight V, Gilbert BE. Ribavirin aerosol treatment of influenza [Review]. Infect Dis Clin North Am 1987;1(2):441-57.
151. Hayden FG, Sabie CA, Connor JD, Lane J. Intravenous ribavirin by constant infusion for serious influenza and parainfluenza virus infection. Antiviral Therapy 1996;1:51-6.
152. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996;275(4): 295-9.
153. Hayden FG. Combination antiviral therapy for respiratory virus infections. Antiviral Res 1996;29(1):45-8.
154. Martin MA, Bock MJ, Pfaller MA, Wenzel RP. Respiratory syncytial virus infections in adult bone marrow transplant recipients [Letter]. Lancet 1988;1(8599):1396-7.
155. Hertz MI, Englund JA, Snover D, Bitterman PB, McGlave PB. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature [Review]. Medicine 1989;68(5):269-81.
156. Win N, Mitchell D, Pugh S, Russell NH. Successful therapy with ribavirin of late onset respiratory syncytial virus pneumonitis complicating allogeneic bone transplantation. Clin Lab Haematol 1992;14(1):29-32.
157. DeVincenzo JP, Leombuno D, Soiffer RJ, Siber GR. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant 1996;17(6):1051-6.
158. th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, 1998, San Diego, CA;593.
159. Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994;169(4):775-81.
160. Englund JA, Piedra PA, Whimbey EA. Prevention and treatment of respiratory syncytial virus and parainfiuenza viruses in immunocompromised patients. Am J Med 1997;102(3A):61-70.
161. th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:351-9.
162. th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:419-20.
163. th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:162-3.
164. th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:483-7.
165. Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors. J Clin Oncol 1995;13(4):1023-35.
166. Riley DK, Pavia AT, Beatty PG, Denton D, Carroll KC. Surveillance cultures in bone marrow transplant recipients: worthwhile or wasteful? Bone Marrow Transplant 1995;15(3):469-73.
167. Walsh TJ. Role of surveillance cultures in prevention and treatment of fungal infections. National Cancer Institute Monograph No. 9;1990:43-5.
168. Crawford SW. Bone-marrow transplantation and related infections. Semin Respir Infect 1993;8(3):183-90.
169. Goodman JL, Winston DJ, Greenfield RA, et al. Controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326(13):845-51.
170. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole
171. Reed EC. Infectious complications during autotransplantation [Review]. Hematol Oncol Clin North Am 1993;7:717-35.
172. th International Symposium on Infections in the Immunocompromised Host, Assisi, Italy, June 23-26, 1996.
173. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis - a contraindication to marrow transplantation? Blood 1994;84(8):2811-4.
174. Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol 1989;5(2):131-42.
175. Weems JJ Jr, Davis BJ, Tablan OC, Kaufman L, Martone WJ. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. Infect Control 1987;8(2):71-5.
176. Krasinski K, Holzman RS, Hanna B, Greco MA, Graff M, Bhogal M. Nosocomial fungal infection during hospital renovation. Infection Control 1985;6(7):278-82.
177. Thio CL, Smith D, Merz WG, et al. Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit. Infect Control Hosp Epidemiol 2000;21(1):18-23.
178. Rhame FS, Streifel AJ, Kersey JH Jr, McGlave PB. Extrinsic risk factors for pneumonia in the patient at high risk of infection [Review]. Am J Med 1984;76(5A):42-52.
179. nd. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 1986;153(3):634-7.
180. American Institute of Architects Academy of Architecture for Health, with assistance from the US Department of Health and Human Services. Guidelines for design and construction of hospital and medical facilities. Washington, DC: American Institute of Architects Press, 1996-67:58.
181. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173(5):1208-15.
182. Kruger W, Stockschlader M, Russman B, et al. Experience with liposomal amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation. Br J Haematol 1995;91(3):684-90.
183. Ringdén O, Tollemar J, Dahllof G, Tyden G. High cure rate of invasive fungal infections in immunocompromised children using AmBisome. Transplant Proc 1994;26(1):175-7.
184. Andstrom EE, Ringdén O, Remberger M, Svahn BM, Tollemar J. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 1996;39(5-6):185-93.
185. O'Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994;12(4):827-34.
186. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991;91(5):484-92.
187. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165(5):891-7.
188. Wade JC. Chapter 5: epidemiology of Candida infections. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis and treatment. New York, NY: Raven Press, Ltd., 1993:85-107.
189. Tollemar J, Ringdén O, Andersson S, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993;25(1 part 2):1495-7.
190. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990;5(6):403-6.
191. Cleary JD, Taylor JW, Chapman SW. Itraconazole in antifungal therapy. Ann of Pharmacother 1992;26(4):502-9.
192. Jennings TS, Hardin TC. Treatment of aspergillosis with itraconazole [Review]. Annals of Pharmacother 1993;27(10):1206-11.
193. Poirier JM, Berlioz F, Isnard F, Chrymol G. Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations. Thérapie 1996;51(2):163-7.
194. Prentice AG, Warnock DW, Johnson SA, Phillips MJ, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994;34(2):247-52.
195. rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, LA, 1993;268.
196. Ortho Biotech, Inc. Itraconazole. In: Physician's desk reference (PDR), Montvale, NJ: Medical Economics Company, 2000:2131-4.
197. Denning DW. Invasive aspergillosis [Review]. Clin Infect Dis 1998;26(4):781-803; quiz 804-5.
198. McWhinney PHM, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17(3):397-404.
199. Lupinetti FM, Behrendt DM, Giller RH, Trigg ME, de Alarcon P. Pulmonary resection for fungal infection in children undergoing bone marrow transplantation. J Thorac Cardiovasc Surg 1992;104(3):684-7.
200. Richard C, Romon I, Baro J, et al. Invasive pulmonary aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome. Bone Marrow Transplant 1993;12(3):237-41.
201. Brazinsky JH, Phillips JE. Pneumocystis pneumonia transmission between patients with lymphoma. JAMA 1969;209(10):1527.
202. Chave JP, David S, Wauters JP, Van Meller G, Francioli P. Transmission of Pneumoystic carinii from AIDS patients to other immunosuppressed patients: a cluster of Pneumo-cystis carinii pneumonia in renal transplant patients. AIDS 1991;5(8):927-32.
203. Goesch TR, Götz G, Stellbrinck KH, Albrecht H, Weh HJ, Hossfeld DK. Possible transfer of Pneumocystis carinii between immunodeficient patients [Letter]. Lancet 1990;336(8715): 627.
204. Bensousan T, Garo B, Islam S, Bourbigot B, Cledes J, Garre M. Possible transfer of Pneumocystic carinii between kidney transplant recipients [Letter]. Lancet 1990;336(8722):1066-7.
205. Ruskin J, Remington JS. Compromised host and infection. I: Pneumocystic carinii pneumonia. JAMA 1967;202(12):1070-4.
206. Watanabe JM, Chinchinian H, Weitz C, McIlvanie SK. Pneumocystis carinii pneumonia in a family. JAMA 1965;193(8):685-6.
207. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992;10(3):267-72.
208. Maltezou HC, Petropoulos D, Choroszy M, et al. Dapsone for Pneumocystic carinii prophylaxis in children undergoing bone marrow transplantation [Review]. Bone Marrow Transplant 1997;20(10):879-81.
209. Link H, Vöhringer H-F, Wingen F, Bragas B, Schwardt A, Ehninger G. Pentamidine aerosol prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant 1993;11(5):403-6.
210. Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immuno-deficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999;180(2):369-76.
211. Nunn PP, Allistone JC. Resistance to trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia: implication of folinic acid. Chest 1984;86(1):149-50.
212. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprimsulfamethoxazole for Pneumocystic carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis 1994;170(4):912-7.
213. Martino R, Martínez, Brunet S, Sureda A. Successful bone marrow transplantation in patients with recent Pneumocystis carinii pneumonia: report of two cases [Letter]. Bone Marrow Transplant 1995;16(3):491.
214. Castagnola E, Dini G, Lanino E, et al. Low CD4 lymphocyte count in a patient with P. carinii pneumonia after autologous bone marrow transplantation. Bone Marrow Transplant 1995;15(16):977-8.
215. Derouin F, Devergie A, Auber P, et al. Toxoplasmosis in bone marrow transplant recipients: report of seven cases and review [Review]. Clin Infect Dis 1992;15(2):267-70.
216. th Annual American Society of Hematology Meeting, San Diego, CA, December 5-9, 1997;224A.
217. Siegel SE, Lunde MN, Gelderman AH, et al. Transmission of toxoplasmosis by leukocyte transfusion. Blood 1971;37(4):388-94.
218. Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant 1994;13(5): 549-57.
219. Jurges E, Young Y, Eltumi M, et al. Transmission of toxoplasmosis by bone marrow transplant associated with Campath-1G. Bone Marrow Transplant 1992;9(1):65-6.
220. Chandrasekar PH, Momin F, Bone Marrow Transplant Team. Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of the literature. Bone Marrow Transplant 1997;19(7):685-9.
221. Foot ABM, Garin YJF, Ribaud P, Devergie A, Derouin F, Gluckman E. Prophylaxis of toxoplasmosis with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant 1994;14(2):241-5.
222. Peacock JE Jr, Greven CM, Cruz JM, Hurd DD. Fansidar: reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis [Review]? Bone Marrow Transplant 1995;15(6):983-7.
223. Liu LX, Weller PF. Strongyloidiasis and other intestinal nematode infections [Review]. Infect Dis Clin North Am 1993;7(3):655-82.
224. Conway DJ, Atkins NS, Lillywhite JE, et al. Immunodiagnosis of Strongyloides stercoralis infection: a method for increasing the specificity of the indirect ELISA. Trans R Soc Trop Med Hyg 1993;87(2):173-6.
225. rd edition. New York, NY: Plenum Medical Book Company, 1994;275-334.
226. Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995;9(4):1005-44.
227. Leiby DA, Fucci MH, Stumpf RJ. Trypanosoma cruzi in a low-to moderate-risk blood donor population: seroprevalence and possible congenital transmission. Transfusion 1999;39(3):310-5.
228. Dictar M, Sinagra A, Verón MT, et al. Recipients and donors of bone marrow transplants suffering from Chagas' disease: management and preemptive therapy of parasitemia. Bone Marrow Transplant 1998;21(4):391-3.
229. Moraes-Souza H, Bordin JO. Strategies for prevention of transfusion-associated Chagas' disease. Transfus Med Rev 1996;10(3):161-70.
230. Altclas J, Sinagra A, Jaimovich G, et al. Reactivation of chronic Chagas' disease following allogeneic bone marrow transplantation and successful pre-emptive therapy with benznidazole. Transplant Infectious Disease 1999;1:135-7.
231. Altclas J, Jaimovich G, Milovic V, Klein F, Feldman L. Chagas' disease after bone marrow transplantation. Bone Marrow Transplant 1996;18(2):447-8.
232. nd ed. Philadelphia, PA: Lippincott Williams & Wilkins 1999;1211-21.
233. Streifel AJ, Marshall JW. Parameters for ventilation controlled environments in hospitals. In: Moschandreas DJ, ed. Design, construction, and operation of healthy buildings; solutions to global and regional concerns. Atlanta, GA: American Society of Heating, Refrigerating and Air-Conditioning Engineers Press, 1998;305-9.
234. Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar airflow isolation. J Hosp Infect 1989;14(2):89-94.
235. Sheretz FJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial Aspergillus infections: unique risk to bone marrow transplant recipients. Am J Med 1987;83(4):709-18.
236. Walter EA, Bowden RA. Infection in the bone marrow transplant recipient [Review]. Infect Dis Clin North Am 1995;9(4):823-47.
237. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. N Engl J Med 1983;308(6):302-7.
238. nd ed. St. Louis, MO: Mosby, 2000 (in press).
239. nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999;1047-53.
240. Carter CD, Barr BA. Infection control issues in construction and renovation. Infect Control Hosp Epidemiol 1997;18(8):587-96.
241. Loo VG, Bertrand C, Dixon C, et al. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. Infect Control Hospital Epidemiol 1996;17(6):360-4.
242. Rask DR, Dziekan B, Swincicki WC, et al. Air quality control during renovation in health care facilities. In: Moschandreas DJ, ed. Design, construction, and operation of healthy buildings; solutions to global and regional concerns. Atlanta, GA: American Society of Heating, Refrigerating, and Air-Conditioning Engineers Press, 1998:291-304.
243. CDC. Laboratory performance evaluation of N95 filtering facepiece respirators, 1996. MMWR 1998;47(48):1045-9.
244. CDC. Guidelines for preventing the transmission Mycobacterium tuberculosis in health-care facilities, 1994. MMWR 1994;43(No. RR-13):1-132.
245. CDC/National Institute of Occupational Safety and Health. Protect yourself against tuberculosis - a respiratory protection guide for health care workers. Cincinnati, OH: US Department of Health and Human Services, US Public Health Service, CDC, National Institute for Occupational Health and Safety, 1995; DHHS publication no. (NIOSH) 96-102:1-132. Available at 〈http:// www.cdc.gov/niosh〉. Accessed May 15, 2000.
246. Rutala WA. APIC guideline for selection and use of disinfectants. AmJ Infect Control 1996;24(4):313-42.
247. National Antimicrobial Information Network. List of EPA registered products. Available at 〈http://ace.orst.edu/info/nain/ lists.htm〉. Accessed May 15, 2000.
248. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Hospital Infection Control Practices Advisory Committee. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999;20(4):247-80 or Am J Infect Control 1999;27(2):97-134.
249. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Hospital Infection Control Practices Advisory Committee. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999;20(4):247-80 or Am J Infect Control 1999;27(2):97-134.
250. Garner JS, Favero MS. Guideline for handwashing and hospital environmental control, 1985; supersedes guideline for hospital environmental control published in 1981. Available at 〈http://www.cdc.gov/ncidod/hip/Guide/handwash.htm〉. Accessed May 15, 2000.
251. Rotter ML. Chapter 87: hand washing and hand disinfection. In: Mayhall CG, ed. Hospital epidemiology and infection control. Baltimore, MD: Lippincott Williams and Wilkins, 1999:1339-55.
252. Larson EL. APIC guideline for handwashing and hand antisepsis in health care settings. Am J Infect Control 1995;23(4):251-69.
253. th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts, San Francisco, CA, 1999;635.
254. CDC/National Center for Infectious Diseases/Hospital Infections Program. Sterilization or disinfection of medical devices: general principles. Atlanta, GA: US Department of Health and Human Services, CDC, 2000. Available at 〈http://www.cdc.gov/ncidod/hip/ sterile/sterilgp.htm〉. Accessed May 15, 2000.
255. Favero MS, Bond WW. Chapter 24: sterilization, disinfection, and antisepsis in the hospital. In: Hauser WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of clinical microbiology. Washington DC: American Society for Microbiology, 1991:183-200.
256. nd ed., Philadelphia, PA: Lippincott Williams & Wilkins, 1999:467-76.
257. Rutala WA, Weber DJ. Disinfection of endoscopes: review of new chemical sterilants used for high-level disinfection. Infect Control and Hospital Epidemiol 1999;20(1):69-75; published erratum, Infect Control Hosp Epidemiol 1999;20(5):302.
258. CDC. Nosocomial outbreak of Rhizopus infections associated with Elastoplast® wound dressings - Minnesota. MMWR 1978;27(5):33-4.
259. CDC. Follow-up on Rhizopus infections associated with Elastoplast® bandages-United States. MMWR 1978;27(28):243-4.
260. Bryce EA, Walker M, Scharf S, et al. Outbreak of cutaneous aspergillosis in a tertiary-care hospital. Infect Control Hosp Epidemiol 1996;17(3):170-2.
261. McCarty JM, Flam MS, Pullen G, Jones R, Kassel SH. Outbreak of primary cutaneous aspergillosis related to intravenous arm boards. J Pediatr 1986;108(5 Pt 1):721-4.
262. Mitchell SJ, Gray J, Morgan MEI, Hocking MC, Durbin GM. Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. Lancet 1996;348(9025):441-3.
263. Gerson SL, Parker P, Jacobs MR, Creger R, Lazarus HM. Aspergillosis due to carpet contamination [Letter]. Infect Control Hosp Epidemiol 1994;15(4 Pt 1):221-3.
264. th Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, May 14-18, 1989:462.
265. Staib F. Ecological and epidemiological aspects of Aspergilli pathogenic for man and animal in Berlin (West). Zentrablatt fur Bakteriologie, Mikrobiologie, und Hygiene - Series A 1984;257(2):240-5.
266. CDC. ABCs of safe and healthy child care: an on-line handbook for child care providers. Atlanta, GA: US Department of Health and Human Services, CDC, 2000. Available at 〈http://www.cdc.gov/ncidod/ hip/ABC/abc.htm〉. Accessed May 15, 2000.
267. Buttery JP, Alabaster SJ, Heine RG, et al. Multiresistant Pseudomonas aeruginosa outbreak in a pediatric oncology ward related to bath toys. Pediatr Infect Dis J 1998;17(6):509-13.
268. CDC. Immunization of health care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee. MMWR 1997;46(No. RR-18):1-42.
269. Bolyard EA, Tablan OC, Williams WW, et al. Guideline for infection control in health care personnel. Infect Control Hospital Epidemiol 1998;19(6):407-63.
270. Stover BH, Bratcher DF. Varicella-zoster virus: infection, control, and prevention [Review]. Am J Infect Control 1998;26(3):369-83; quiz 382-4.
271. nd ed. Oxford, England: Blackwell Science, Inc., 1999;751-63.
272. Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy [Review]. Semin Oncol 1998;25(5):538-51.
273. th Annual Epidemic Intelligence Service Conference, April 19-23, 1999, Atlanta, GA;47.
274. Do AN, Ray BJ, Banerjee SN, et al. Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. J Infect Dis 1999;179(2):442-8.
275. Kool JL, Fiore AE, Kioski CM, et al. More than 10 years of unrecognized nosocomial transmission of Legionnaires' disease among transplant patients. Infect Control Hosp Epidemiol 1998;19(12):898-904.
276. CDC. Sustained transmission of nosocomial Legionnaires' disease -Arizona and Ohio. MMWR 1997;46(19):416-21.
277. Lepine LA, Jernigan DB, Butler JC, et al. Recurrent outbreak of nosocomial Legionnaires' disease detected by urinary antigen testing: evidence for long-term colonization of a hospital plumbing system. Infect Control Hosp Epidemiol 1998;19(12):905-10.
278. Muraca PW, Yu VL, Goetz A. Disinfection of water distribution systems for Legionella : a review of application procedures and methodologies [Review]. Infect Control Hosp Epidemiol 1990;11(2):79-88.
279. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999;43(6):1412-6.
280. Leski TA, Gniadkowski M, Skoczynska A, Stefaniuk E, Trzcinski K, Hryniewicz W. Outbreak of mupirocin-resistant Staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. J Clin Microbiol 1999;37(9):2781-8.
281. Schmitz FJ, Lindenlauf E, Hofmann B, et al. Prevalence of low- and high-level mupirocin resistance in Staphylococci from 19 European hospitals. J Antimicrob Chemother 1998;42(4):489-95.
282. Irish D, Eltringham I, Teall A, et al. Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. J Hosp Infect 1998;39(1):19-26.
283. Udo EE, Farook VS, Mokadas EM, Jacob LE, Sanyal SC. Molecular fingerprinting of mupirocin-resistant methicillin-resistant Staphylococcus aureus from a burn unit. Int J Infect Dis 1998-99;3(2):82-7.
284. Bastos MC, Mondino PJ, Azevedo ML, Santos KR, Giambiagi-deMarval M. Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin. Eur J Clin Microbiol Infect Dis 1999;18(6):393-8.
285. CDC. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995;44(No. RR-12):1-13.
286. CDC. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR 1997;46(35):813-5.
287. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340(7):493-501.
288. CDC. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 1997;46(27):626-35.
289. CDC. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR 1997;46(27):624-35.
290. Waldvogel FA. New resistance in Staphylococcus aureus. N Engl J Med 1999;340(7):556-7.
291. Montecalvo MA, Shay DK, Patel P, et al. Bloodstream infections with vancomycin-resistant Enterococci. Arch Intern Med 1996;156:1458-62.
292. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-13.
293. Kirkpatrick BD, Harrington SM, Smith D, et al. Outbreak of vancomycin-dependent Enterococcus faecium in a bone marrow transplant unit. Clin Infect Dis 1999;29(5):1268-73.
294. Byers KE, Durbin LJ, Simonton BM, Anglim AM, Adel KA, Farr BM. Disinfection of hospital rooms contaminated with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1998;19(4):261-4.
295. Trick WE, Kuehnert MJ, Quirk SB, et al. Regional dissemination of vancomycin-resistant Enterococci resulting from interfacility transfer of colonized patients. J Infect Dis 1999;180(2):391-6.
296. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis [Review]. Infect Control Hosp Epidemiol 1995;16(8):459-77.
297. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-36; quiz 1035-6.
298. McFarland LV, Mulligan M, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;321(3):204-10.
299. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990;88(2):137-40.
300. Pear SM, Williamson T, Bettin K, Gerding DN, Galgiami JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120(4):272-7.
301. Kaatz GW, Gitlin SD, Schaberg DR et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988;127(6):1289-94.
302. Delmee M, Vandercam B, Avesani V, Michaux JL. Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. EurJ Clin Microbiol 1987;6(6):623-7.
303. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. Ann Intern Med 1992;117(4):297-302.
304. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G. Prevention of antibiotic associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96(4):981-8.
305. Niault M, Thomas F, Prost J, Ansai FH, Kalfon P. Fungemia due to Saccbaromyces species in a patient treated with enterai Saccharomyces boulardii. Clin Infect Dis 1999;28:930.
306. Fox JP, Brandt CD, Wasserman FE, et al. Virus watch program: a continuing surveillance of viral infections in metropolitan New York families. VI: observations of adenovirus infections: virus excretion patterns, antibody response, efficacy of surveillance, patterns of infections, and relation to illness. Am J Epidemiol 1969;89(1):25-50.
307. Hillis WO, Cooper MR, Bang FB. Adenovirus infection in West Bengal. I: persistence of viruses in infants and young children. Indian J Med Res 1973;61(7):980-8.
308. Hall CB, Powell KR, MacDonald DE, et al. Respiratory syncytial virus infection in children with compromised immune function. New Engl J Med 1986;315(2):77-81.
309. Villarino ME, Burman W, Wang YC, et al. Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection. JAMA 1999;281(2):169-71.
310. American Thoracic Society/CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161(4, part 2):S221-47.
311. th ed. Elk Grove Village, IL: American Academy of Pediatrics;2000:593-613.
312. CDC. Notice to readers: use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons. MMWR 1998;47(42):911-2.
313. Fennelly KP. Transmission of tuberculosis during medical procedures [Letter]. Clin Infect Dis 1997;25:1273-5.
314. Talbot EA, Perkins MD, Silva SFM, Frothingham R. Disseminated Bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis 1997;24(6):1139-46.
315. CDC. Role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR 1996;45(No. RR-4):13.
316. nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999:1285-317.
317. CDC/National Center for Infectious Diseases/Working Group on Waterborne Cryptosporidiosis. Cryptosporidium and water: a public health handbook. Atlanta, GA: US Department of Health and Human Services, CDC, 1997. Available at 〈http:// www.cdc.gov/ncidod/diseases/crypto/crypto.pdf〉. Accessed May 15, 2000.
318. CDC/National Center for Infectious Diseases. Cryptosporidiosis [Fact sheet]. Atlanta, GA: US Department of Health and Human Services, CDC, 1999. Available at 〈http:/ /www.cdc.gov/ncidod/dpd/parasites/cryptosporidiosis/ factsht_cryptosporidiosis.htm〉. Accessed May 15, 2000.
319. th ed. Elk Grove Village, IL: American Academy of Pediatrics 2000:223-4.
320. th ed. Washington, DC: American Public Health Association, 2000:134-7.
321. DiFranza JR, Lew RA. Morbidity and mortality in children associated with the use of tobacco products by other people. Pediatrics 1996;97(4):560-8.
322. Cohen S, Tyrrell DA, Russell MA, Jarvis MJ, Smith AP. Smoking, alcohol consumption, and susceptibility to the common cold. Am J Pub Health 1993;83(9):1277-83.
323. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997;16:979-83.
324. Lipsky BA, Boyko EJ, Inui TS, Koepsell TD. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986;146:2179-85.
325. Hall CB, Hall WJ, Gala CL, MaGill FB, Leddy JP. Long-term prospective study in children after respiratory syncytial virus infection. J Pediatr 1984;105(3):358-64.
326. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. New Engl J Med 2000;342(10):681-9.
327. Levitz SM, Diamond RD. Aspergillosis and marijuana [Letter]. Ann Intern Med 1991;115(7):578-9.
328. Marks WH, Florence L, Lieberman J, et al. Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient [Review]. Transplant 1996;61(12):1771-4.
329. Chusid MJ, Gelfand JA, Nutter C, Fauci AS. Letter: pulmonary aspergillosis, inhalation of contaminated marijuana smoke, chronic granulomatous disease. Ann Intern Med 1975;82(5):682-3.
330. Hamadeh R, Ardehali A, Locksley RM, York MK. Fatal aspergillosis associated with smoking contaminated marijuana in a marrow transplant recipient. Chest 1988;94(2):432-3.
331. Kurup VP, Resnick A, Kagen SL, Cohen SH, Fink JN. Allergenic fungi and actinomycetes in smoking materials and their health implications. Mycopathologia 1983;82(1):61-4.
332. Kagen SL. Aspergillus : an inhalable contaminant of marihuana. N Engl J Med 1981;304(8):483-4.
333. Schwartz IS. Marijuana and fungal infection [Letter]. Am J Clin Pathol 1985;84(2):256.
334. Schwartz IS. Non-Aspergillus sinusitis and marijuana use [Letter]. AmJ Clin Pathol 1992;97(4):601-2.
335. Llamas R, Hart R, Schneider NS. Allergic bronchopulmonary aspergillosis associated with smoking moldy marihuana. Chest 1978;73(6):871-2.
336. Angulo FJ, Glaser CA, Juranek DD, Lappin MR, Regnery RL. Caring for pets of immunocompromised persons. J Am Vet Med Assoc 1994;205(12):1711-8.
337. Elliott DL, Tolle SW, Goldberg L, Miller JB. Pet-associated illness. New Engl J Med 1985;313(16):985-94.
338. Glaser CA, Angulo FJ, Rooney JA. Animal-associated opportunistic infections among persons infected with the human immunodeficiency virus. Clin Infect Dis 1994;18:14-24.
339. Adams RM. Animals in schools: a zoonosis threat? Pediatr Infect Dis J 1998;17(2):174-6.
340. Dalton C, Hoffman R, Pape J. Iguana-associated salmonellosis in children. Pediatr Infect Dis J 1995;14(4):319-20.
341. CDC. Reptile-associated salmonellosis - selected states, 1996-1998. MMWR 1999;48(44):1009-13.
342. CDC. Errata: Reptile-associated salmonellosis - selected states, 1996-1998. MMWR 1999;48(45):1051.
343. Mermin J, Hoar B, Angulo FJ. Iguanas and Salmonella marina infection in children: a reflection of the increasing incidence of reptile-associated salmonellosis in the United States. Pediatr 1997;99(3):399-402.
344. CDC. Salmonellosis associated with chicks and ducklings -Michigan and Missouri, Spring 1999. MMWR 2000;49(14):297-9.
345. CDC. Lake-associated outbreak of Escherichia coli O157:H7 -Illinois, 1995. MMWR 1996;45(21):437-9.
346. CDC. Outbreak of cryptosporidiosis associated with a water sprinkler foundation - Minnesota, 1997. MMWR 1998;47(40):856-60.
347. Kramer MH, Sorhage FE, Goldstein ST, Dalley E, Wahlquist SP, Herwaldt BL. First reported outbreak in the United States of cryptosporidiosis associated with a recreational lake. Clin Infect Dis 1998;26(1):27-33.
348. al-Eissa YA, Kambal AM, al-Nasser MN, al-Habib SA, al-Fawaz IM, al-Zamil FA. Childhood brucellosis: a study of 102 cases. Pediatr Infect Dis J 1990;9(2):74-9.
349. Keene WE, Hedberg K, Herriott DE, et al. Prolonged outbreak of Escherichia coli O157:H7 infections caused by commercially distributed raw milk. J Infect Dis 1997;176(3):815-8.
350. CDC. Outbreak of Escherichia coli O157:H7 infections associated with drinking unpasteurized commercial apple juice - British Columbia, California, Colorado, and Washington, October 1996. MMWR 1996;45(44):975.
351. CDC. Outbreaks of Escherichia coli O157:H7 infection and cryptosporidiosis associated with drinking unpasteurized apple cider-Connecticut and New York, October 1996. MMWR 1997;46(1):4-8.
352. CDC. Outbreak of Salmonella serotype Muenchen infections associated with unpasteurized orange juice - United States and Canada, June 1999. MMWR 1999;48(27): 582-5.
353. CDC/National Center for Infectious Diseases. Handle and prepare food safely. Atlanta, GA: US Department of Health and Human Services, CDC, 2000. Available at 〈http://www.cdc.gov/ncidod/op/ food.htm〉. Accessed May 15, 2000.
354. CDC. Outbreak of Campylobacter enteritis associated with cross-contamination of food - Oklahoma, 1996. MMWR 1998;47(7):129-31.
355. CDC. Outbreaks of Salmonella serotype enteritidis infection associated with consumption of raw shell eggs - United States, 1994-1995. MMWR 1996;45(34):737-42.
356. CDC. Foodborne outbreak of cryptosporidiosis - Spokane, Washington, 1997. MMWR 1998;47(27):565-7.
357. US Department of Agriculture/Food Safety and Inspection Service. Big thaw - safe defrosting methods. Washington, DC: US Department of Agriculture, Food Safety and Inspection Service, Consumer Education and Information, 1996;1-2. Available at 〈http://www.fsis.usda.gov/OA/news/bigthaw.htm〉. Accessed May 15, 2000.
358. US Department of Agriculture/Food Safety and Inspection Service. Kitchen thermometers. Washington, DC: US Department of Agriculture Consumer, Food Safety and Inspection Service, Education and Information, 2000 (in press).
359. Moe GL. Chapter 12: low-microbial diets for patients with granulocytopenia. In: Bloch AS, ed. Nutrition management of the cancer patient. Rockville, AID: Aspen Publishing, Inc., 1990:125-34.
360. rd ed. New York, NY: Churchill Livingstone, 2000:1501-14.
361. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992;116(5):353-7.
362. CDC. Vibrio vulnificus infections associated with eating raw oysters - Los Angeles, 1996. MMWR 1996;45(29):621-4.
363. CDC. Outbreak of Vibrio parahaemolyticus infection associated with eating raw oysters and clams harvested from Long Island Sound -Connecticut, New Jersey, and New York, 1998. MMWR 1999;48(03):48-51.
364. CDC. Viral gastroenteritis associated with eating oysters -Louisiana, December 1996-January 1997. MMWR 1997;46(47):1109-12.
365. Fayer R, Lewis EJ, Trout JM, et al. Cryptosporidium parvum in oysters from commercial harvesting sites in Chesapeake Bay. Emerg Infect Dis 1999;5(5):706-10.
366. Oliver MR, van Voorhis WC, Boeckh M, Mattson D, Bowden RA. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 1996;22:521-4.
367. CDC. Health Information for international travel 1999-2000. Atlanta, GA: US Department of Health and Human Services, CDC, 1999. Available at 〈http://www.cdc.gov/travel/yellowbk99.pdf〉. Accessed May 16, 2000.
368. World Health Organization. Guide on safe food for travelers. Geneva, Switzerland: World Health Organization, 1997:1-4. Available at 〈http://www.who.int/dsa/cat98/trav8.htm〉. Accessed May 15, 2000.
369. CDC/National Center for Infectious Diseases. Food and water precautions and traveler's diarrhea prevention. Atlanta, GA: US Department of Health and Human Services, CDC, 2000;1-2. Available at 〈http://www.cdc.gov/travel/foodwatr.htm〉. Accessed May 15, 2000.
370. Belay E, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye's syndrome in the United States from 1981 through 1997. New Engl J Med 1999;340(18):1377-82.
371. Pauksen K, Hammarström V, Ljungman P, et al. Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994;18(4):547-52.
372. Pauksen K, Duraj V, Ljungman P, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant 1992;9(6):427-32.
373. Ljungman P, Wiklund-Hammarsten M, Duraj V, et al. Responses to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990;162(2):496-500.
374. Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989;159(4):610-5.
375. Henning KJ, White MH, Sepkowitz KA, Armstrong D. National survey of immunization practices following allogeneic bone marrow transplantation. JAMA 1997;277(14):1148-51.
376. Padley D, Koontz F, Trigg ME, Gingrich R, Strauss RG. Bacterial contamination rates following processing of bone marrow and peripheral blood progenitor cell preparations. Transfusion 1996;36(1):53-6.
377. th ed. Minneapolis, MN: National Marrow Donor Program, 1999:1-35.
378. Progenitor Cell Standards Task Force. Standards for hematopoietic progenitor cells. Bethesda, MD: American Association of Blood Banks, 1996:1-36.
379. st ed.-North America. Omaha, NE: FAHCT Accreditation Office, 1996:1-58.
380. Food and Drug Administration. Memorandum, June 8, 1995: recommendations for the deferral of current and recent inmates of correctional institutions as donors of whole blood, blood components, source leukocytes, and source plasma. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 1995. Available at 〈http://www.fda.gov/cber/ bldmem/6_8_95.txt〉. Accessed May 16, 2000.
381. American Association of Blood Banks. New uniform donor history questionnaire issued [Association bulletin 99-10]. American Association of Blood Banks News 1999;(Nov/Dec):13-21.
382. CDC. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR 1994;43(No. RR-8):1-17.
383. CDC. Public health service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 1991;40(No. RR-4):1-17.
384. Food and Drug Administration. Suitability determination for donors of human cellular and tissue-based products [Proposed rule]. Federal Register 1999;64:52696-723. Available at 〈http://wwv.fda.gov/cber/ rules/suitdonor.pdf〉. Accessed May 16, 2000.
385. Wells GM, Woodward TE, Fisct P, Hornick RB. Rocky Mountain spotted fever caused by blood transfusion. JAMA 1978;239(26):2763-65.
386. Herwaldt BL, Kjemtrup AM, Conrad PA, et al. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite. J Infect Dis 1997;175(5):1259-62.
387. Dobroszycki J, Herwaldt BL, Boctor F, et al. Cluster of transfusion-associated babesiosis cases traced to a single asymptomatic donor. JAMA 1999;281(10):927-30.
388. CDC. Q fever - California. MMWR 1977;26(10):86, 91.
389. CDC. Transmission of Colorado tick fever virus by blood transfusion -Montana. MMWR 1975;24:422-7.
390. th ed. Bethesda, MD: American Association of Blood Banks, 1999:1-98.
391. Klein MB, Miller JS, Nelson CM, Goodman JL. Primary bone marrow progenitors of both granulocytic and monocytic lineages are susceptible to infection with the agent of human granulocytic ehrlichiosis. J Infect Dis 1997;176(5):1405-9.
392. Dharmasena F, Gordon-Smith EC. Transmission of malaria by bone marrow transplantation [Letter]. Transplant 1986;42(2):228.
393. Villeneuve L, Cassaing S, Magnaval JF, et al. Plasmodium falcifarum infection following allogeneic bone-marrow transplantation. Ann Trop Med Parasitol 1999;93(5):533-5.
394. Leiby DA, Lenes BA, Tibbals MA, Tames-Olmedo MT. Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. New Engl J Med 1999; 341(16):1237-9.
395. Leiby DA, Read EJ, Lenes BA, et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. J Infect Dis 1997;176:1047-52.
396. Dodd RY. Transmission of parasites by blood transfusion [Review]. Vox Sang 1998;74(suppl 2):161-3.
397. Food and Drug Administration. Guidance for industry: precautionary measures to reduce the possible risk of transmission of zoonoses by blood and blood products from xenotransplantation products recipients and their contacts - 12/ 23/99 [Draft guidance]. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 1999;1-11. Available at 〈http://www.fda.gov/cber/guidelines.htm〉. Accessed May 16, 2000.
398. CDC. Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts - Japan, January 1979-May 1996. MMWR 1997;46(45):1066-9.
399. Food and Drug Administration. Guidance for industry: revised precautionary measures to reduce die possible risk of transmission of Creutzfeldt-Jakob Disease (CJD) and new variant Creutzfeldt-Jakob disease (nvCJD) by blood and blood products - 11/23/99. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 1999;1-16. Available at 〈http://www.fda.gov/ cber/guidelines.htm〉. Accessed May 16, 2000.
400. Will RG, Alpers MP, Dormont D, Schonberger LB, Tateishi J. Infectious and sporadic prion diseases. In: Prusiner SB, ed. Prion biology and diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1999:465-507.
401. Food and Drug Administration. Memorandum, April 23, 1992: revised recommendations for the prevention of Human Immunodeficiency Virus (HIV) transmission by blood and blood products. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, 1992:1-24. Available at 〈http://www.fda.gov/cber/ memo.htm〉. Accessed May 16, 2000.
402. Pugatch D, Mileno M, Rich JD. Possible transmission of human immunodeficiency virus type 1 from body piercing. Clin Infect Dis 1998;26(3):767-8.
403. CDC. 1995 revised guidelines for prophylaxis against Pneumocystic carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995;44(No. RR-4):1-11.
404. Attarian H, Bensinger WI, Buckner CD, McDonald DL, Rowley SD. Microbial contamination of peripheral blood stem cell collections. Bone Marrow Transplant 1996;17(5):699-702.
405. Rowley SD, Davis J, Dick J, et al. Bacterial contamination of bone marrow grafts intended for autologous and allogeneic bone marrow transplantation: incidence and clinical significance. Transfusion 1988;28(2):109-12.
406. Webb IJ, Coral FS, Andersen JW, et al. Sources and sequelae of bacterial contamination of hematopoietic cell components: implications for the safety of hematotherapy and graft engineering. Transfusion 1996;36(9):782-8.
407. Meyers JD, Huff JC, Holmes KK, Thomas ED, Bryan JA. Parenterally transmitted hepatitis A associated with platelet transfusions: epidemiologic study of an outbreak in a marrow transplantation center. Ann Intern Med 1974;81(2):145-51.
408. Fountain D, Ralston M, Higgins N, et al. Liquid nitrogen freezers: a potential source of microbial contamination of hematopoietic stem cell components. Transfusion 1997;37(6):585-91.
409. Nasser RM, Hajjar I, Sandhaus LM, et al. Routine cultures of bone marrow and peripheral stem cell harvests: clinical impact, cost analysis, and review. Clin Infect Dis 1998;27(4):886-8.
410. Flake AW, Roncarolo MG, Puck JM, et al. Treatment of x-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med 1996;335(24):1806-10.
411. Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation: a status report. JAMA 1997;278(11):932-7.